Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.61 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.61 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.52 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10512419 | 0.83 | CYSLTR1 (0.56) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL9210004 | 0.82 | CYSLTR1 (0.51) | CYSLTR1CYSLTR2PDE10AGPBAR1HTR1B | |
| SCHEMBL9081199 | 0.81 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL10689480 | 0.81 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL10662425 | 0.81 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL10683765 | 0.81 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL9843295 | 0.81 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL6582909 | 0.81 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL9363352 | 0.81 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL6027036 | 0.80 | PDE10A (0.59) | CYSLTR1CYSLTR2PDE10AGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126004-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS | Rogne Bioscience Inc. (US) | 2017-02-08 | — | — | EP | claimed |
| WO-2015153838-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS | ROGNE BIOSCIENCE INC. (US) | 2015-10-08 | — | — | WO | claimed |
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | claimed |
| US-20110256130-A1 | METHODS OF TREATING INFLAMMATORY DISORDERS | SQUARE 1 BANK | 2011-10-20 | — | — | US | claimed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | claimed |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | claimed |
| WO-2010065491-A2 | METHODS OF TREATING INFLAMMATORY DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | claimed |
| WO-2010056910-A2 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| EP-0223368-B1 | SUBSTITUTED NAPHTHALENE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-12-27 | — | — | EP | claimed |
| US-4732978-A | RESPIRATORY SYSTEM DISORDERS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-03-22 | — | — | US | claimed |
| EP-0223368-A1 | Substituted naphthalene derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-05-27 | — | — | EP | claimed |
| US-20220347306-A1 | SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | AVELAS ACQUISITION CORPORATION | 2022-11-03 | — | — | US | disclosed |
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | AVELAS ACQUISITION CORPORATION | 2021-03-18 | — | — | US | disclosed |
| EP-3781194-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | Avelas Biosciences, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3755371-A1 | COMBINATION CANCER THERAPY WITH ANTI-CANCER AGENTS AND ANTIBODIES TARGETING A COMPLEX COMPRISING NON-CLASSICAL HLA-I AND NEOANTIGEN | Abexxa Biologics, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-6376528-B1 | SYNERGISTIC MIXTURE | G. D. SEARLE & CO. | 2002-04-23 | — | — | US | disclosed |
| EP-0223368-B1 | SUBSTITUTED NAPHTHALENE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-12-27 | — | — | EP | disclosed |
| US-4732978-A | RESPIRATORY SYSTEM DISORDERS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-03-22 | — | — | US | disclosed |
| US-4732978-A | RESPIRATORY SYSTEM DISORDERS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-03-22 | — | — | US | disclosed |
| EP-0223368-A1 | Substituted naphthalene derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347306-A1 | SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | PAICS, TIE1, ANTXR2 | CYSLTR1 2792/4885CYSLTR2 2398/4885PDE10A 3058/4885 |
| US-20110256130-A1 | METHODS OF TREATING INFLAMMATORY DISORDERS | TNF, MPO, MMP8 | CYSLTR1 80/4885CYSLTR2 54/4885PDE10A 1281/4885 |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | TNNI3, TNNT2, FABP3 | CYSLTR1 1203/4885CYSLTR2 1067/4885PDE10A 675/4885 |
| US-20210079039-A1 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | PAICS, ANXA3, APOB | CYSLTR1 3284/4885CYSLTR2 2965/4885PDE10A 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.